European urology最新文献

筛选
英文 中文
Re: Pierre-Etienne Gabriel, Alec Zhu, Paolo Gontero, Morgan Rouprêt, Evanguelos Xylinas, John P Sfakianos. BCG-unresponsive NMIBC: An Obsolete Definition in a Multimodal and Evolving Therapeutic Landscape. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.028 回复:Pierre-Etienne Gabriel, Alec Zhu, Paolo Gontero, Morgan Rouprêt, Evanguelos Xylinas, John P sakianos。脑脊髓炎无反应的NMIBC:在多模式和不断发展的治疗前景中一个过时的定义。Urol欧元。在出版社。http://dx.doi.org/10.1016/j.eururo.2026.03.028
IF 23.4 1区 医学
European urology Pub Date : 2026-10-01 DOI: 10.1016/j.eururo.2026.09.021
Marie-Pier St-Laurent,Peter C. Black
{"title":"Re: Pierre-Etienne Gabriel, Alec Zhu, Paolo Gontero, Morgan Rouprêt, Evanguelos Xylinas, John P Sfakianos. BCG-unresponsive NMIBC: An Obsolete Definition in a Multimodal and Evolving Therapeutic Landscape. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.028","authors":"Marie-Pier St-Laurent,Peter C. Black","doi":"10.1016/j.eururo.2026.09.021","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.021","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"12 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149092033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congress Calendar 国会的日历
IF 29.1 1区 医学
European urology Pub Date : 2026-10-01 Epub Date: 2026-10-06 DOI: 10.1016/j.eururo.2026.09.011
{"title":"Congress Calendar","authors":"","doi":"10.1016/j.eururo.2026.09.011","DOIUrl":"10.1016/j.eururo.2026.09.011","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages e95-e96"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149094496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: PSMA PET for Lymph Nodes in Intermediate-risk PC 回复:PSMA PET检查中危PC淋巴结。
IF 29.1 1区 医学
European urology Pub Date : 2026-10-01 Epub Date: 2026-04-30 DOI: 10.1016/j.eururo.2026.04.025
Laura Evangelista, Angelo Porreca
{"title":"Re: PSMA PET for Lymph Nodes in Intermediate-risk PC","authors":"Laura Evangelista, Angelo Porreca","doi":"10.1016/j.eururo.2026.04.025","DOIUrl":"10.1016/j.eururo.2026.04.025","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Page 433"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Impact of Circulating Tumor DNA and Copy-number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated with Salvage High-dose Chemotherapy 再:循环肿瘤DNA和拷贝数改变对挽回性高剂量化疗治疗复发/难治性生殖细胞肿瘤临床结局的影响:博客标题:ctDNA在晚期生殖细胞肿瘤中的价值。
IF 29.1 1区 医学
European urology Pub Date : 2026-10-01 Epub Date: 2026-06-20 DOI: 10.1016/j.eururo.2026.05.011
Levi Holland, Scott Eggener
{"title":"Re: Impact of Circulating Tumor DNA and Copy-number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated with Salvage High-dose Chemotherapy","authors":"Levi Holland, Scott Eggener","doi":"10.1016/j.eururo.2026.05.011","DOIUrl":"10.1016/j.eururo.2026.05.011","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Page 437"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer 关于:EORTC 1333/PEACE-3试验中恩杂鲁胺加镭223治疗转移性去势抵抗性前列腺癌的最终总生存期结果
IF 29.1 1区 医学
European urology Pub Date : 2026-10-01 Epub Date: 2026-06-17 DOI: 10.1016/j.eururo.2026.05.012
Edoardo Francini
{"title":"Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer","authors":"Edoardo Francini","doi":"10.1016/j.eururo.2026.05.012","DOIUrl":"10.1016/j.eururo.2026.05.012","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Page 438"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Emanuele Messina, Antonella Borrelli, Alessandro Sciarra, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2025;89:246–57 回复:Emanuele Messina, Antonella Borrelli, Alessandro Sciarra等。原发性非对比磁共振成像前列腺癌筛查:随机临床试验(PROSA)。欧元2025;89:246-57
IF 29.1 1区 医学
European urology Pub Date : 2026-10-01 Epub Date: 2026-08-05 DOI: 10.1016/j.eururo.2026.04.035
Stefano De Luca, Luca Ferrando, Francesco Porpiglia
{"title":"Re: Emanuele Messina, Antonella Borrelli, Alessandro Sciarra, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2025;89:246–57","authors":"Stefano De Luca, Luca Ferrando, Francesco Porpiglia","doi":"10.1016/j.eururo.2026.04.035","DOIUrl":"10.1016/j.eururo.2026.04.035","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Page e91"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901) 中期PSMA-PET肿瘤总体积对ENZA-p总生存期的预后价值,ENZA-p是一项Enzalutamide与Enzalutamide Plus的随机2期试验[177Lu] Lu-PSMA-617 (ANZUP1901)。
IF 29.1 1区 医学
European urology Pub Date : 2026-10-01 Epub Date: 2026-04-08 DOI: 10.1016/j.eururo.2026.03.026
Louise Emmett, Nathan Papa, Oliver Sartor, Michael J. Morris, Shalini Subramaniam, Megan Crumbaker, Narjess Ayati, Jeffrey Chen, Ken Herrmann, Andrei Gafita, Mina Swiha, Anthony M. Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Bao Ho, Sobia Khan, Ian D. Davis
{"title":"Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)","authors":"Louise Emmett,&nbsp;Nathan Papa,&nbsp;Oliver Sartor,&nbsp;Michael J. Morris,&nbsp;Shalini Subramaniam,&nbsp;Megan Crumbaker,&nbsp;Narjess Ayati,&nbsp;Jeffrey Chen,&nbsp;Ken Herrmann,&nbsp;Andrei Gafita,&nbsp;Mina Swiha,&nbsp;Anthony M. Joshua,&nbsp;Andrew Weickhardt,&nbsp;Sze-Ting Lee,&nbsp;Siobhan Ng,&nbsp;Roslyn J. Francis,&nbsp;Jeffrey C. Goh,&nbsp;David A. Pattison,&nbsp;Bao Ho,&nbsp;Sobia Khan,&nbsp;Ian D. Davis","doi":"10.1016/j.eururo.2026.03.026","DOIUrl":"10.1016/j.eururo.2026.03.026","url":null,"abstract":"<div><h3>Background and objective</h3><div>Interim [<sup>68</sup>Ga]Ga-prostate-specific membrane-antigen positron emission tomography/computed tomography (PSMA-PET/CT) has prognostic potential for overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC), although evidence is limited. This ENZA-p sub-study evaluated 3-mo PSMA-total-tumor-volume (PSMA-TTV) as a prognostic biomarker for OS with enzalutamide ± [<sup>177</sup>Lu]Lu-PSMA-617.</div></div><div><h3>Methods:</h3><div>ENZA-p is a randomized, phase 2 trial. Participants with mCRPC and risk factors for early treatment failure with enzalutamide were randomized (1:1) to enzalutamide or enzalutamide + [<sup>177</sup>Lu]Lu-PSMA-617. Participants underwent baseline and 3-mo [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT, quantified to derive PSMA-TTV. We evaluated the prognostic value of PSMA-TTV change, and residual PSMA-TTV at 3-mo for OS (NCT04419402).</div></div><div><h3>Key findings and limitations:</h3><div>This sub-study included 152/162 (94%) randomized participants with a 3-mo PSMA-PET. Median OS was 27 mo (95% confidence interval [CI] 23–30). Baseline median PSMA-TTV 230 ml (interquartile range [IQR] 75–635) and 3-mo PSMA-TTV 103 ml (IQR 24–457). The median change in PSMA-TTV from baseline was –34% (IQR –76% to 16%) with 50/152 (33%) participants with increase in PSMA-TTV. Any increase versus decrease in PSMA-TTV at 3-mo was associated with shorter OS (HR 2.52, 95% CI 1.65–3.85) and decreased 2-yr survival 30% (95% CI 17–43) versus 67% (95% CI 56–75) (log-rank <em>p</em> &lt; 0.0001). Residual 3-mo PSMA-TTV higher versus lower than the median (103 ml) was associated with shorter OS (HR 3.76, 95% CI 2.39–5.92) and lower 2-yr survival 34% (95% CI 23–45) versus 76% (95% CI 64–84) (log-rank <em>p</em> &lt; 0.0001). This association was independent of treatment arm and prostate-specific antigen (PSA) response.</div></div><div><h3>Conclusions and clinical implications:</h3><div>PSMA-TTV at 3 mos was prognostic for OS independent of study treatment and PSA response in ENZA-p, warranting further prospective validation of interim PSMA-PET response criteria.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 333-343"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial STAMPEDE试验中开始长期激素治疗的高危局限性或转移性前列腺癌患者的主要不良心血管事件
IF 23.4 1区 医学
European urology Pub Date : 2026-10-01 DOI: 10.1016/j.eururo.2026.09.001
Omar El-Taji,Peter Dutey-Magni,Mick Brown,Macey Murray,Claire Amos,Duncan Gilbert,Max Parmar,Louise Brown,Matthew Sydes,Gert Attard,Nicholas James,Noel W. Clarke,Ashwin Sachdeva
{"title":"Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial","authors":"Omar El-Taji,Peter Dutey-Magni,Mick Brown,Macey Murray,Claire Amos,Duncan Gilbert,Max Parmar,Louise Brown,Matthew Sydes,Gert Attard,Nicholas James,Noel W. Clarke,Ashwin Sachdeva","doi":"10.1016/j.eururo.2026.09.001","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.001","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"36 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial 微超引导与mri引导前列腺癌活检诊断:最佳随机临床试验
IF 23.4 1区 医学
European urology Pub Date : 2026-10-01 DOI: 10.1016/j.eururo.2026.09.007
Rossano Girometti,Francesco Giganti
{"title":"Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial","authors":"Rossano Girometti,Francesco Giganti","doi":"10.1016/j.eururo.2026.09.007","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.007","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"1 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Daoyuan Li’s Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol 2026;90:176 关于:卡介苗-谷氨酰胺联合丝裂霉素与卡介苗-谷氨酰胺单独治疗卡介苗芽孢杆菌Guérin-naïve非肌肉侵袭性膀胱癌:一项随机3期试验(ANZUP 1301)。Urol欧元。在出版社。http://dx.doi.org/10.1016/j.eururo.2026.03.011。
IF 29.1 1区 医学
European urology Pub Date : 2026-10-01 Epub Date: 2026-05-22 DOI: 10.1016/j.eururo.2026.04.033
Dickon Hayne, Alison Y. Zhang, Hayley Thomas, Andrew D. Redfern, Ian D. Davis, Martin R. Stockler
{"title":"Reply to Daoyuan Li’s Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol 2026;90:176","authors":"Dickon Hayne,&nbsp;Alison Y. Zhang,&nbsp;Hayley Thomas,&nbsp;Andrew D. Redfern,&nbsp;Ian D. Davis,&nbsp;Martin R. Stockler","doi":"10.1016/j.eururo.2026.04.033","DOIUrl":"10.1016/j.eururo.2026.04.033","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Page 435"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147990189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书